Elenco dei centri specialistici della Regione Toscana, per la cura […]
Search Results for: Nuovo algoritmo identifica le alterazioni del DNA coinvolte nei tumori
Here's what we've found for you
Friuli Venezia Giulia
Elenco dei centri specialistici della Regione Friuli Venezia Giulia, per […]
Campania
Avellino – Ospedale San Giuseppe Moscati Ambulatorio Ostetricia e Ginecologia […]
Piemonte
Elenco dei centri specialistici della Regione Piemonte, per la cura […]
UniBa sperimenta una pasta che riduce il colesterolo cattivo
Limitate alterazioni metaboliche indotte da farmaci psichiatrici
Strumento di intelligenza artificiale identifica i tipi di demenza
I ricercatori della Mayo Clinic hanno sviluppato un nuovo strumento […]
Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer
This diagnostic study assesses the accuracy of an investigational blood-based circulating tumor DNA test for detection of colorectal cancer in an asymptomatic average-risk population.
Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada
This study estimates how cell-free DNA screening impacts clinical and economic outcomes in Canada compared with existing screening approaches (fecal immunochemical tests or colonoscopies).
Come la caffeina può rallentare l’invecchiamento cellulare
Uno studio della Queen Mary University di Londra ha scoperto che la […]
Una scoperta sul sistema immunitario rivela una potenziale soluzione all’Alzheimer
Gli scienziati della Facoltà di Medicina dell’Università della Virginia hanno studiato la […]
Prevalence of low-level viremia in the treatment of chronic hepatitis B in China: a systematic review and meta-analysis
Objectives
Low-level viremia (LLV) is a risk factor affecting the prognosis of patients with chronic hepatitis B (CHB). The objective of this study was to systematically assess the prevalence of LLV, thereby providing robust evidence-based medical insights into effective clinical interventions and preventative measures against LLV.
Design
Systematic review and meta-analysis.
Data sources
A comprehensive literature search was conducted across various databases, including China National Knowledge Infrastructure, Wanfang Data (Wanfang), China Science And Technology Journal Database (VIP-CSTJ), China Biology Medicine disc (CBMdisc), PubMed, Embase, Web of Science and the Cochrane Library, spanning from the inception of these databases up to 5 January 2024.
Eligibility criteria
The research type included either a cross-sectional study or a cohort study focusing on the Chinese population, with the outcome being LLV. The languages were limited to both Chinese and English. Studies with any of the following were excluded: subjects with other comorbidities, original articles inaccessible or data unavailable, and duplicate publications.
Data extraction and synthesis
Literature management used EndNote X9.1, and an information extraction table was created using Microsoft Excel to record research information, including first author, year of publication and study type. The prevalence of LLV was assessed via meta-analysis. Meta-analyses were conducted in RStudio using the ‘metaprop ()’ function. Subgroup analysis and sensitivity analysis were used to identify sources of heterogeneity, and funnel plots and AS-Thompson tests were employed to evaluate publication bias.
Results
18 studies, encompassing a total sample of 9773 patients, were included in the analysis. Of these, 3336 patients were identified with LLV. The meta-analysis revealed that the prevalence of LLV among treated CHB patients stands at 33.6% (95% CI 30.2 to 37.0). The antigen status, antiviral treatment regimen (type of drugs and nucleos(t)ide analogues (NAs)), treatment duration, medication adherence and baseline hepatitis B virus DNA levels all affected the prevalence of LLV. Sensitivity analysis further corroborated the stability of these meta-analysis findings. The funnel plot and AS-Thompson test indicated no significant publication bias (t = –0.01, p=0.995).
Conclusions
The prevalence of LLV among CHB patients was established at 33.7% (95% CI 29.8% to 37.6%). Thus, it is imperative for clinical decision-makers to consider the various influencing factors of LLV when formulating treatment plans in order to mitigate any potential adverse outcomes.
Tumori, la metà dei decessi è dovuta a cause evitabili
Al primo posto il fumo seguito da infezioni, alcol e sovrappeso
Speranze da trattamento meno invasivo per raro tumore della colonna vertebrale
Studio dell’Istituto nazionale tumori su terapia non chirurgica
Tumore colonna vertebrale, speranze da trattamento meno invasivo
Studio dell’Istituto nazionale tumori su terapia non chirurgica
Tumori neuroendocrini, passo avanti contro quelli avanzati
Via libera ad una nuova molecola dal comitato Ema, si riduce la progressione della malattia
Tumori, a Milano la prima termoablazione con risonanza magnetica
Intervento su fegato. “Innovazione trattamento neoplasie”